Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 21Terminated 8Withdrawn 3Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Neuroendocrine Tumors 52Thyroid Neoplasms 19Thyroid Cancer, Papillary 16Carcinoma, Neuroendocrine 16Pheochromocytoma 11Adrenocortical Carcinoma 11Thyroid Carcinoma, Anaplastic 10Gastro-enteropancreatic neuroendocrine tumor 10Small Cell Lung Carcinoma 9Paraganglioma 9Multiple Endocrine Neoplasia Type 1 9Pituitary Neoplasms 8Lung Neoplasms 8Adenoma, Islet Cell 8Sarcoma 7Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Carcinoma, Medullary 6Adenocarcinoma, Follicular 6Colorectal Neoplasms 5Central Nervous System Neoplasms 5Carcinoma, Renal Cell 5Carcinoma, Merkel Cell 5Carcinoid Tumor 5Somatostatinoma 4Pancreatic Neoplasms 4Neuroblastoma 4Neoplasm Metastasis 4Cholangiocarcinoma 4Carcinoma, Hepatocellular 4

Interventions

Temozolomide 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Carcinoma, Islet Cell × Endocrine × Clear all
NCT01824875 2026-02-25

Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
144 enrolled 15 charts
Endocrine

Glucagonoma, Insulinoma, Adenoma, Islet Cell, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡